The United Kingdom and the United States have established a important bilateral deal that will ensure zero duties on British pharmaceutical shipments being sold in the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has agreed to increase funding on pharmaceuticals through the National Health Service (NHS). This move secures that duties on these vital goods will be held at zero for a period of three years.
This deal is in response to earlier threats to hike duties on branded drug imports, with figures floated reaching double the cost.
"This deal with the Britain strengthens the worldwide climate for innovative medicines and brings much-needed balance to transatlantic pharmaceutical trade," a statement noted.
Trade Importance
Medicines constitute one of the Britain's biggest export categories to the America, which is easily the biggest buyer for large companies like GSK and AstraZeneca.
Statistics indicate that in the 12 months to the end of last September, the UK sold pharmaceutical products totaling billions to the US. This figure accounted for nearly one-fifth of total UK exports in that period.
"This deal secures employment, stimulates funding and facilitates the UK to establish itself as a international leader for medical research," a minister remarked.
Detailed British Pledges
The agreement includes several specific pledges from the UK:
- Price Threshold Increase: The UK will increase the price threshold at which it judges new therapies to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a goal to increase overall public funding on treatments from 0.3 percent of GDP to 0.6% over the next decade.
- Payback Limit: The amount manufacturers must refund to the NHS to control costs will be capped at fifteen percent. In the past, repayments exceeded twenty percent.
Recent Tensions
The deal takes place against a protracted row between the drug companies and the UK government over drug pricing and approval rates.
These tensions were heightened by claims that American customers were charged several times more for the identical medicines than patients in the UK and Europe.
Recently, several large manufacturing plans in the UK have been paused or abandoned, while multi-billion-dollar investments have been announced toward US facilities.
A senior figure acknowledged that the NHS must spend more on drugs, noting that its spending on drugs had decreased as a proportion of its resources over the previous ten-year period.
